SCHEMBL6463791

SCHEMBL6463791

Cc1c(O)ccc(OC(=O)c2ccccc2)c1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.53
MAPT P10636 4/20 0.53
ESR1 P03372 4/20 0.53
ESR2 Q92731 4/20 0.53
MEN1 O00255 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
GAA P10253 2/20 0.53
JAK2 O60674 1/20 0.53
USP2 O75604 1/20 0.53
ALOX15 P16050 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
HSD17B10 Q99714 1/20 0.53
SLC6A3 Q01959 1/20 0.50
POLB P06746 3/20 0.46
SERPINE1 P05121 1/20 0.46
TSHR P16473 1/20 0.46
LMNA P02545 2/20 0.44
F2 P00734 1/20 0.44
CYP3A4 P08684 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2292938 0.86 ESR1 (0.66) KMT2AMAPTESR1ESR2MEN1
SCHEMBL2679682 0.82 KMT2A (0.63) KMT2AMAPTESR1ESR2MEN1
SCHEMBL1786230 0.81 KMT2A (0.51) KMT2AMAPTESR1ESR2MEN1
SCHEMBL6406532 0.81 MAPT (0.44) KMT2AMAPTESR1ESR2MEN1
SCHEMBL16236624 0.80 KMT2A (0.47) KMT2AMAPTESR1ESR2MEN1
SCHEMBL8766843 0.79 ESR1 (0.51) KMT2AMAPTESR1ESR2MEN1
SCHEMBL9744231 0.79 MAPT (0.56) KMT2AMAPTESR1ESR2MEN1
SCHEMBL777822 0.78 CA1 (0.55) KMT2AMAPTESR1ESR2MEN1
SCHEMBL1816359 0.78 ALDH1A1 (0.50) KMT2AMAPTMEN1SMN1; SMN2GAA
Benzoic Acid SCHEMBL7184961 0.78 HTT (0.53) MAPTSMN1; SMN2ALOX15NPSR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124687-A1 Process for synthesizing d-tocotrienols COULADOUROS ELIAS A (GR) 2005-06-09 US disclosed
WO-2005035490-A2 PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS YASOO HEALTH, INC. (US) 2005-04-21 WO disclosed
US-5393776-A Tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia BRISTOL-MYERS SQUIBB COMPANY (US) 1995-02-28 US disclosed
EP-0571928-A1 Acyclic Tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia Bristol-Myers Squibb Company (US) 1993-12-01 EP disclosed
EP-0476493-A1 Acyclic tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia Bristol-Myers Squibb Company (US) 1992-03-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124687-A1 Process for synthesizing d-tocotrienols UGT8, DDOST, GGPS1 KMT2A 1679/4885MAPT 4791/4885ESR1 3170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.